OBJECTIVES Treatment delays in patients with wAMD and DME are very important since they are associated with disease progression. This is the first study in Greece to highlight patient’s access delays’ to treatment and to estimate the burden of diseases in Greece. METHODS An expert panel with 11 ophthalmologists was convened. The experts came from six out of seven Regional Health Authorities, covering geographically the largest part of the country. A 13-page questionnaire was developed and validated. The Delphi technique was used to collect data on resource use and disease management, patient access delays, and indirect costs. Unit costs were retrieved from NHS sources and the analysis was conducted from the societal perspective, including direct costs incurred by patients, their families and the health care system, and indirect costs, of productivity losses. RESULTS Total cost of managing wAMD during the first year of treatment was estimated at €20,660, 32.8% of which consisted of direct costs (drug acquisition and administration, follow-up, lab and imaging tests), and 67.2% of which included non-medical and indirect costs (caregivers). Direct medical cost per DME patient for the first year of treatment was estimated at €6,066, while the non-medical and indirect costs were estimated at €12,271, resulting in a total cost of €18,337 per patient per year. 91% of the experts agreed that there are significant delays in patient access to specific treatments (average 20 days); all agreed (100%) that these delays lead to faster disease progression, and a strong majority (>80%) supported that they lead to deterioration of patients’ QoL. CONCLUSIONS There are significant costs associated with the management of wAMD and DME in Greece, 70% of which is incurred by patients and their families. Administrative procedures leading to patient access delays should be minimized in order to avoid disease progression and associated costs.